Arecor Therapeutics plc
(“Arecor” or the “Group”)
FIRST PRODUCT INCORPORATING ARECOR’S ARESTAT TECHNOLOGY, AT220, LAUNCHED IN EUROPE
First commercial sale triggers milestone payment and future royalties to Arecor
News
Bristol Myers Squibb's (BMS) Augtyro (repotrectinib) has been approved by the US Food and Drug Administration (FDA) to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Lung cancer is the leading cause of cancer deaths in the US, with NSCLC representing up to 85% of all lung cancer diagnoses.
More common in individuals with little to no smoking history, the ROS1 gene alteration occurs in only up to 2% of NSCLC patients and is associated with aggressive lung cancer that can often spread to the brain.
The University of Glasgow and Kadans Science Partner, supported by Scottish Enterprise, are delighted to announce the construction of a new Health Innovation Hub in Govan, setting the stage for a thriving life sciences cluster in the area.
Work on the new Health Innovation Hub has begun, and is due for completion in summer 2025. Morrison Construction have been appointed as the main contractor. The Hub will attract new innovative businesses into the area, and deliver local benefits to the community through job creation.
Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital with participation from Sanofi Ventures and the University of Cambridge Venture Fund
Unique transgenic mouse platform harnesses natural power of T cells to build a portfolio of first-in-class cancer medicines
Appointment of Big Pharma executive strengthens leadership team to drive ambitious growth strategy
Coventry, UK, 10 November 2023: NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director. Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for the next stage in its development.
Tessellate BIO, an Emerging Precision Oncology Company Announces the Appointment of World-Leading Scientists to its Scientific Advisory Board
Amsterdam, the Netherlands and London, UK – 15 November 2023 - Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment of multiple international experts to its Scientific Advisory Board.
ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines
- ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases with unmet clinical need
- Series A led by 4BIO Capital, BGF, and UCB Ventures with participation from the Cystic Fibrosis Foundation, Eli Lilly and Company and existing investors including Origin Capital, Meltwind and O2H
The experienced life science logistics company, Biocair, provides critical logistics support to a cutting-edge research project into drugs that can treat, and prevent, one of the world’s more serious medical conditions, fibrosis.
Biocair is supporting the innovative, UK-based contract research company, FibroFind, to deliver precious project samples from its pre-clinical research studies to pharmaceutical companies across the world. So far, Biocair has accomplished over 100 rapid, reliable sample deliveries worldwide for FibroFind.
Cambridge Life Sciences is the trusted name in in vitro diagnostic assay kits and we are delighted to be showcasing them at Medica 2023 on the UK Pavilion in Hall 16.
We have 4 key product kits – Paracetamol Assay, Salicylate Assay, Endosc-Hp® Rapid Urease Test and Autozyme® autoimmune kits.
“With our products being trusted in the UK’s highly renowned NHS for over 40 years, we are seeking to find new distributors to get us known across Europe and Medica is the ideal place to meet with them.” said John Gannon, Chief Commercial Officer”.
~ Company also ranked amongst 100 Best Companies for Women twice in a row
Mumbai, 3rd Nov, 2023: Thermo Fisher Scientific in India has once again been recognized with two prestigious awards, strengthening its position as a leading workplace in the country. The company has been certified as a Great Place to Work by the Great Place to Work Institute for the fifth consecutive year and ranked among the 100 Best Companies for Women in India for the second year in a row by Avtar and Seramount.